169 related articles for article (PubMed ID: 34569417)
1. Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
Appiah-Kubi P; Iwuchukwu EA; Soliman MES
J Biomol Struct Dyn; 2022; 40(23):13115-13126. PubMed ID: 34569417
[TBL] [Abstract][Full Text] [Related]
2. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
[TBL] [Abstract][Full Text] [Related]
3. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
[TBL] [Abstract][Full Text] [Related]
4. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis.
Moonsamy S; Dash RC; Soliman ME
Molecules; 2014 Apr; 19(4):5243-65. PubMed ID: 24762964
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
6. Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.
Bai Q; Zhang Y; Li X; Chen W; Liu H; Yao X
Phys Chem Chem Phys; 2014 Nov; 16(44):24332-8. PubMed ID: 25296959
[TBL] [Abstract][Full Text] [Related]
7. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
Xu GG; Guo J; Wu Y
Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
[TBL] [Abstract][Full Text] [Related]
8. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
9. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
10. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop.
Tamamis P; Floudas CA
PLoS One; 2014; 9(4):e95767. PubMed ID: 24763408
[TBL] [Abstract][Full Text] [Related]
11. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
[TBL] [Abstract][Full Text] [Related]
12. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
[TBL] [Abstract][Full Text] [Related]
15. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
Nakata H; Maeda K; Das D; Chang SB; Matsuda K; Rao KV; Harada S; Yoshimura K; Ghosh AK; Mitsuya H
Sci Rep; 2019 Mar; 9(1):4828. PubMed ID: 30886166
[TBL] [Abstract][Full Text] [Related]
16. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
[TBL] [Abstract][Full Text] [Related]
17. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential CCR5 inhibitors through pharmacophore-based virtual screening, molecular dynamics simulation and binding free energy analysis.
Wang J; Shu M; Wang Y; Hu Y; Wang Y; Luo Y; Lin Z
Mol Biosyst; 2016 Oct; 12(11):3396-3406. PubMed ID: 27714030
[TBL] [Abstract][Full Text] [Related]
19. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
Xie X; Zheng YG; Chen H; Li J; Luo RH; Chen L; Zheng CB; Zhang S; Peng P; Ma D; Yang LM; Zheng YT; Liu H; Wang J
J Med Chem; 2022 Dec; 65(24):16526-16540. PubMed ID: 36472561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
